Artesian-Arts

Mirikizumab Shows Continued Symptom Improvement and Reduction of Intestinal Inflammation in Patients with Crohn’s Disease in 52-Week Phase 2 Trial

INDIANAPOLIS, Oct. 12, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) announced today new efficacy and…